GH
Guardant Health, Inc.
GH lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
GH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
GH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
GH PE Valuation
GH has no meaningful PE right now: it lost money over the past year.
GH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GH's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
GH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.69 | -$0.48 |
| Q2 2026 | -$3.50 | -$0.15 |
| Q1 2026 | -$3.40 | -$0.01 |
| Q4 2025 | -$3.32 | +$0.24 |
| Q3 2025 | -$3.21 | +$1.03 |
| Q2 2025 | -$3.35 | +$0.74 |
| Q1 2025 | -$3.39 | +$0.53 |
| Q4 2024 | -$3.56 | +$0.72 |
GH is still losing money, but less than at its worst: $3.69 per share over the past year, against $6.50 at its worst in early 2023.
GH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $361M | +36% |
| Q2 2026 | $335M | +44% |
| Q1 2026 | $301.7M | +48% |
| Q4 2025 | $281.3M | +39% |
| Q3 2025 | $265.2M | +39% |
| Q2 2025 | $232.1M | +31% |
| Q1 2025 | $203.5M | +21% |
| Q4 2024 | $201.8M | +30% |
GH's revenue has grown year over year every quarter since late 2020: $361M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -37% | +0.5 points |
| Q2 2026 | -39% | +7.3 points |
| Q1 2026 | -40% | +14 points |
| Q4 2025 | -43% | +20 points |
| Q3 2025 | -37% | +24 points |
| Q2 2025 | -46% | +11 points |
| Q1 2025 | -55% | +4.6 points |
| Q4 2024 | -62% | +65 points |
GH's operating margin was −37% last quarter, up 0.5 points from the same quarter a year ago, near the top of its range since 2019.
GH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | +$8.6M |
| Q2 2026 | -$69.5M | -$3.6M |
| Q1 2026 | -$71.2M | -$4.1M |
| Q4 2025 | -$54.2M | +$29.2M |
| Q3 2025 | -$45.8M | +$9.5M |
| Q2 2025 | -$65.9M | +$33.1M |
| Q1 2025 | -$67.1M | -$29.9M |
| Q4 2024 | -$83.4M | -$583K |
GH has burned cash in almost every quarter: −$232M over the past year, against −$262M the year before.
GH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | +7.7% | +9.6M shares |
| 3 years | +14% | +16.7M shares |
| 5 years | +33% | +33M shares |
| Available history | +48% | +43.8M shares |
GH has 134M diluted shares, up 7.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $45M |
| Q4 2019 | — |
GH hasn't bought back shares in the past year.
GH Net Leverage
GH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.5 | Neutral |
| Stochastic | 45.3 | Neutral |
GH's weekly RSI is 52 (neutral) and its Stochastic is 45 (neutral).
GH PE vs Healthcare Sector
GH has no meaningful PE right now: it lost money over the past year.
GH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $166.8 | 7.2% below |
| 20 week MA | $164.2 | 5.7% below |
| 50 week MA | $128.2 | 21% above |
| 100 week MA | $90.8 | 71% above |
| 200 week MA | $59.1 | 162% above |
GH has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 162% above its 200-week average.
GH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $133.8 | +70% |
| 2021 | $133.8 | $97.5 | -27% |
| 2022 | $97.5 | $27.9 | -71% |
| 2023 | $27.9 | $27.1 | -3% |
| 2024 | $27.1 | $30.4 | +13% |
| 2025 | $30.4 | $103.0 | +238% |
| 2026 YTD | $103.0 | $154.9 | +50% |
GH's yearly returns have swung widely, from +238% in 2025 to −71% in 2022. It's up 50% so far in 2026.